AVALGLUCOSIDASE ALFA-NGPT: 741 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
741
Total FAERS Reports
3 (0.4%)
Deaths Reported
74
Hospitalizations
741
As Primary/Secondary Suspect
5
Life-Threatening
6
Disabilities
Prescription
Status
FDA Application: 761194 ·
First Report: 20201019 · Latest Report: 20250910
What Are the Most Common AVALGLUCOSIDASE ALFA-NGPT Side Effects?
#1 Most Reported
Drug specific antibody present
124 reports (16.7%)
#2 Most Reported
Off label use
76 reports (10.3%)
#3 Most Reported
Weight increased
41 reports (5.5%)
All AVALGLUCOSIDASE ALFA-NGPT Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Drug specific antibody present | 124 | 16.7% | 0 | 0 |
| Off label use | 76 | 10.3% | 0 | 2 |
| Weight increased | 41 | 5.5% | 0 | 5 |
| Weight decreased | 34 | 4.6% | 0 | 8 |
| Inappropriate schedule of product administration | 30 | 4.1% | 0 | 6 |
| Fatigue | 28 | 3.8% | 0 | 2 |
| Dyspnoea | 25 | 3.4% | 0 | 3 |
| Pyrexia | 25 | 3.4% | 0 | 6 |
| Illness | 23 | 3.1% | 0 | 2 |
| Headache | 22 | 3.0% | 0 | 3 |
| Condition aggravated | 21 | 2.8% | 0 | 5 |
| Product preparation error | 20 | 2.7% | 0 | 0 |
| Pruritus | 20 | 2.7% | 0 | 2 |
| Covid-19 | 19 | 2.6% | 0 | 4 |
| Malaise | 18 | 2.4% | 0 | 3 |
| Pneumonia | 17 | 2.3% | 1 | 9 |
| Rash | 16 | 2.2% | 0 | 1 |
| Cough | 15 | 2.0% | 1 | 0 |
| Fall | 15 | 2.0% | 1 | 4 |
| Hypertension | 15 | 2.0% | 0 | 1 |
Who Reports AVALGLUCOSIDASE ALFA-NGPT Side Effects? Age & Gender Data
Gender: 54.5% female, 45.5% male. Average age: 38.0 years. Most reports from: US. View detailed demographics →
Is AVALGLUCOSIDASE ALFA-NGPT Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2020 | 1 | 0 | 0 |
| 2021 | 8 | 0 | 0 |
| 2022 | 82 | 0 | 14 |
| 2023 | 127 | 0 | 12 |
| 2024 | 118 | 1 | 17 |
| 2025 | 79 | 0 | 10 |
What Is AVALGLUCOSIDASE ALFA-NGPT Used For?
| Indication | Reports |
|---|---|
| Glycogen storage disease type ii | 471 |
| Product used for unknown indication | 12 |
AVALGLUCOSIDASE ALFA-NGPT vs Alternatives: Which Is Safer?
AVALGLUCOSIDASE ALFA-NGPT vs AVANAFIL
AVALGLUCOSIDASE ALFA-NGPT vs AVANDAMET
AVALGLUCOSIDASE ALFA-NGPT vs AVANDIA
AVALGLUCOSIDASE ALFA-NGPT vs AVAPRITINIB
AVALGLUCOSIDASE ALFA-NGPT vs AVASTIN
AVALGLUCOSIDASE ALFA-NGPT vs AVATROMBOPAG
AVALGLUCOSIDASE ALFA-NGPT vs AVELOX
AVALGLUCOSIDASE ALFA-NGPT vs AVELUMAB
AVALGLUCOSIDASE ALFA-NGPT vs AVIBACTAM
AVALGLUCOSIDASE ALFA-NGPT vs AVIBACTAM\CEFTAZIDIME
Official FDA Label for AVALGLUCOSIDASE ALFA-NGPT
Official prescribing information from the FDA-approved drug label.